|Articles|March 10, 2023
- Pharmaceutical Executive: March 2023
- Volume 43
- Issue 3
Pharmaceutical Executive, March 2023 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive March 2023 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 3 years ago
Navigating Disruption in the Metapharma Eraalmost 3 years ago
Biopharma M&A: Year in Review, Ripples Aheadalmost 3 years ago
Balancing Pharma Hiring Practices in Good Times and Badalmost 3 years ago
Being KOL-Centric: More Meaningful Expert Engagementalmost 3 years ago
A New Era of Influence: Embracing the KOL-DOL Dynamic in Healthcarealmost 3 years ago
Food for Thought: Make Room for Multiple Opinionsalmost 3 years ago
The Pivot to Digitalalmost 3 years ago
More than Ever, Data Will Dictate Future Fortunesalmost 3 years ago
Generative AI’s Breakthrough Potential in Pharma Marketingalmost 3 years ago
The Challenge of Taking on Falsified Medicines in EuropeNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade
2
Johnson & Johnson Reaches Agreement with Trump Administration, Continues $55 Billion US-Based Investment Plan
3
Roundup: Pharma’s Funding Surge Ahead of J.P. Morgan 2026
4
FDA Limits Regulations on Non-Medical Grade Wearable Fitness Devices
5

